Having trouble accessing articles? Reset your cache.

July 2 Company Quick Takes: Gilead's Truvada REMS removed; plus UC, Amicus/Paragon and Iovance

FDA removes REMS for Truvada
FDA said it is eliminating the REMS for Truvada emtricitabine/tenofovir from Gilead Sciences Inc. (NASDAQ:GILD) and its four generics approved for pre-exposure

Read the full 268 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers